Valentin Fuster

Search results

• Tourmaline Bio Reports Fourth Quarter And Full Year 2024 Financial Results And Recent Business Highlights

  Fuster, V. & Bhatt, D. L.

  13/03/25

  79 items of Media coverage

  Press/Media

• Study shows that atherosclerosis silently affects a large percentage of healthy people

  Fuster, V.

  12/03/25

  1 item of Media coverage

  Press/Media

• CNIC seeks volunteers in Spain for an international project that aims to change cardiovascular prevention

  Fuster, V.

  12/03/25

  1 item of Media coverage

  Press/Media

• New Study to Examine Hypercortisolism in Resistant Hypertension

  Fuster, V. & Bhatt, D. L.

  11/03/25

  1 item of Media coverage

  Press/Media

• Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

  Fuster, V. & Bhatt, D. L.

  10/03/25

  9 items of Media coverage

  Press/Media

• Repair Biotechnologies Announces Appointment of Noted Cardiologist Dr. Deepak L. Bhatt to Scientific Advisory Board

  Fuster, V. & Bhatt, D. L.

  10/03/25

  4 items of Media coverage

  Press/Media

• Repair Biotechnologies Announces Appointment of Noted Cardiologist Dr. Deepak L. Bhatt to Scientific Advisory Board

  Fuster, V. & Bhatt, D. L.

  10/03/25

  1 item of Media coverage

  Press/Media

• Study Findings on Heart Failure Are Outlined in Reports from Icahn School of Medicine at Mount Sinai [Rationale and Design of the Sota-p-cardia Trial (Atru-v): Sotagliflozin In Hfpef Patients Without Diabetes]

  Lam, D., Abascal,, V., Moss, N., Fuster, V., Mancini, D., Lam, D. & Lerakis, S.

  27/02/25

  1 item of Media coverage

  Press/Media

• At Issue: Debate over DAPT duration endures

  Fuster, V. & Bhatt, D. L.

  26/02/25

  1 item of Media coverage

  Press/Media

• New drug therapies targeting Lp(a) could be a breakthrough in cardiovascular care

  Fuster, V. & Bhatt, D. L.

  24/02/25

  1 item of Media coverage

  Press/Media

• US SECTOR WEEKLY: PRESS RELEASES OF LISTED COMPANIES IN THE MEDICAL SECTOR FRIDAY FEBRUARY 21, 2025

  Fuster, V. & Bhatt, D. L.

  21/02/25

  1 item of Media coverage

  Press/Media

• THIS diabetes medication can also reduce risk of heart attack and stroke, Lancet study reveals

  Fuster, V. & Bhatt, D. L.

  20/02/25

  1 item of Media coverage

  Press/Media

• Sotagliflozin significantly lowers Heart Attack and Stroke Risk, reports Lancet study

  Fuster, V. & Bhatt, D. L.

  20/02/25

  1 item of Media coverage

  Press/Media

• THIS diabetes medication can also reduce risk of heart attack and stroke, Lancet study reveals

  Fuster, V. & Bhatt, D. L.

  20/02/25

  1 item of Media coverage

  Press/Media

• Sotagliflozin significantly lowers Heart Attack and Stroke Risk, reports Lancet study

  Fuster, V. & Bhatt, D. L.

  20/02/25

  1 item of Media coverage

  Press/Media

• Drug for diabetes and kidney disease may also lower heart attack, stroke risks

  Fuster, V. & Bhatt, D. L.

  19/02/25

  2 items of Media coverage

  Press/Media

• Drug for diabetes and kidney disease may also lower heart attack, stroke risks

  Fuster, V. & Bhatt, D. L.

  19/02/25

  1 item of Media coverage

  Press/Media

• Sotagliflozin the first drug of its kind to limit heart attacks, strokes in high-risk patients

  Fuster, V.

  19/02/25

  1 item of Media coverage

  Press/Media

• Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

  Fuster, V. & Bhatt, D. L.

  19/02/25

  1 item of Media coverage

  Press/Media

• First-Ever Drug Cuts Heart Attacks, Strokes in Diabetes

  Fuster, V. & Bhatt, D. L.

  19/02/25

  1 item of Media coverage

  Press/Media

• Mount Sinai Health System: A Diabetes, Heart Failure, and Kidney Disease Medication is the First of Its Kind to Significantly Reduce Both Heart Attacks and Strokes

  Fuster, V. & Bhatt, D. L.

  18/02/25

  1 item of Media coverage

  Press/Media

• Published Data In The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits Of Sotagliflozin To Reduce Major Adverse Cardiovascular Events (MACE)

  Fuster, V. & Bhatt, D. L.

  18/02/25

  6 items of Media coverage

  Press/Media

• A Diabetes, Heart Failure, and Kidney Disease Medication is the First of Its Kind to Significantly Reduce Both Heart Attacks and Strokes

  Fuster, V. & Bhatt, D. L.

  18/02/25

  1 item of Media coverage

  Press/Media

• New Anti-Diabetic Drug Sotagliflozin Reduces Heart Disease and Stroke Risks

  Fuster, V. & Bhatt, D. L.

  18/02/25

  1 item of Media coverage

  Press/Media

• Lexicon Pharmaceuticals: Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

  Fuster, V. & Bhatt, D. L.

  18/02/25

  1 item of Media coverage

  Press/Media